Asahi shares mark weekly slide after cyberattack halts production
Stephen Feider, Chief Financial Officer of Beta Bionics, Inc. (NASDAQ:BBNX), sold 100 shares of common stock at $21.0 per share, for a total of $2100 on September 5, 2025. The stock, which currently trades at $23.13, has shown remarkable strength with a 23% gain in the past week alone, according to InvestingPro data.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed under a Rule 10b5-1 trading plan adopted on May 15, 2025.
On the same day, Feider also exercised options to acquire 100 shares of Beta Bionics common stock at an exercise price of $5.10, for a total value of $509. These options are part of an employee stock option plan, vesting in 48 equal monthly installments from September 14, 2023. The options expire on September 13, 2033.
Following these transactions, Feider directly owns 44,041 shares of Beta Bionics. He also holds options to acquire 99,595 shares.
In other recent news, Beta Bionics reported its second-quarter earnings for 2025, showcasing a significant improvement in financial performance. The company posted an earnings per share (EPS) of -$0.39, surpassing the forecast of -$0.42. Alongside this, Beta Bionics achieved a 54% year-over-year increase in net sales, reaching $23.2 million. Truist Securities responded to these results by raising its price target for the company to $21.00 from $18.00, while maintaining a Buy rating. This adjustment followed the company’s better-than-expected revenue and gross margin, driven by new patient starts and success in the pharmacy benefit provider channel. These developments reflect positive momentum for Beta Bionics, as noted by analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.